Study suggests 1.24-fold increase in lung cancer incidence after severe COVID-19 — Evidence Review

Severe COVID-19 and influenza infections may increase long-term lung cancer risk by creating a pro-tumor environment in the lungs, according to a new study; vaccination appears to prevent many of these changes. Most related research agrees that severe respiratory infections can have lasting negative consequences for lung health, although direct links to increased cancer risk have been less clear until now, as reported by researchers at the UVA Health's Beirne B. Carter Center for Immunology Research.

• Several large-scale studies indicate that respiratory infections such as influenza and COVID-19 are associated with increased risk of lung complications and mortality in cancer patients, yet the explicit relationship between severe infections and future lung cancer risk has only recently begun to emerge 6 9 10.
• Prior research shows a modest increase in lung cancer risk following repeated influenza infections, with risk rising alongside cumulative exposures, supporting the new study's findings that severe viral damage may contribute to oncogenesis 6.
• Most studies focus on short-term outcomes and complications in cancer patients with acute viral infections, whereas the new research provides some of the first evidence linking severe respiratory infection to later cancer development in both animal models and human data 1 2 6.

Study Overview and Key Findings

Understanding the long-term consequences of severe respiratory infections is increasingly important given the global burden of COVID-19 and influenza. The new study addresses a critical gap by exploring whether severe viral injury to the lungs can increase the risk of lung cancer, which has major implications for clinical surveillance and prevention. Unlike prior research that focused primarily on immediate outcomes or acute complications, this work examines persistent immune alterations in the lungs and their potential to promote tumorigenesis over time.

Property	Value
Organization	UVA Health's Beirne B. Carter Center for Immunology Research, UVA Comprehensive Cancer Center, UVA School of Medicine
Journal Name	Cell
Authors	Jie Sun, Wei Qian, Xiaoqin Wei, Andrew J. Barros, Xiangyu Ye, Haibo Zhang, Qing Yu, Samuel P. Young, Eric V Yeatts, Yury Park, Chaofan Li, Sijie Hao, Gislane Almeida-Santos, Jinyi Tang, Harish Narasimhan, Nicole A Kirk, Valeria Molinary, Ying Li, Li Li, Bimal N. Desai, Peter Chen, Kwon-Sik Park, Anny Xiaobo, Jeffrey M. Sturek, Wei Chen, In Su Cheon, Jie Sun
Population	Mice and human patients with severe respiratory infections
Methods	Animal Study
Outcome	Lung cancer incidence and immune changes after severe infections
Results	1.24-fold increase in lung cancer incidence after severe COVID-19

Literature Review: Related Studies

We searched the Consensus paper database, which contains over 200 million research papers, to identify studies relevant to the long-term effects of severe respiratory infections and lung cancer risk. The following search queries were used:

1. lung cancer risk severe COVID-19
2. flu severe illness lung cancer association
3. long-term effects COVID-19 respiratory health

Summary Table of Key Topics and Findings

Topic	Key Findings
Does severe respiratory infection increase lung cancer risk?	- Repeated influenza exposure is associated with increased lung cancer risk, with risk rising with cumulative exposures 6. - Severe COVID-19 hospitalization is linked to higher lung cancer incidence in new research; previous evidence is limited 6.
What are the long-term respiratory effects of severe COVID-19 or flu?	- Persistent respiratory symptoms, lung function abnormalities, and radiographic changes are common after severe COVID-19 or influenza 11 12 13 15. - Long-term health consequences may include organ dysfunction and reduced quality of life 12 14 15.
How do viral infections impact cancer patients' outcomes?	- Cancer patients experience more severe outcomes and higher mortality from influenza and COVID-19 compared to non-cancer patients 1 2 9 10. - Lung cancer and hematological malignancy patients are at especially high risk for complications 2 7 8 9 10.
Can vaccination reduce risks associated with severe respiratory infection?	- Annual influenza vaccination is recommended for cancer patients to reduce infection risk and complications 10. - The new study suggests vaccination may prevent immune changes linked to increased lung cancer risk after severe infection.

---

Does severe respiratory infection increase lung cancer risk?

Previous clinical research on the direct relationship between severe respiratory infections and subsequent lung cancer risk has been sparse. However, the new study provides experimental and observational evidence of increased lung cancer incidence following severe viral pneumonia, particularly severe COVID-19, in both animal models and humans. This aligns with earlier epidemiological findings that repeated influenza exposure is associated with a modestly higher risk of lung cancer, especially with cumulative infections 6.

• The new study reports a 1.24-fold increase in lung cancer incidence after severe COVID-19, consistent with prior findings linking repeated influenza exposure to higher cancer risk (adjusted OR 1.09–1.25, depending on exposure level) 6.
• Prior literature has primarily focused on immediate complications rather than long-term oncogenic risk, making this study a novel contribution 6.
• Past studies have noted confounding factors such as smoking, but the new study found increased risk independent of smoking status and other comorbidities 6.
• The mechanistic insights in the new study, including immune system changes that create a pro-tumor environment, provide biological plausibility for the epidemiological associations 6.

What are the long-term respiratory effects of severe COVID-19 or flu?

A substantial body of research indicates that severe COVID-19 or influenza can lead to persistent respiratory symptoms, abnormal lung function, and imaging changes lasting months or even longer. The new study expands this knowledge by highlighting how such chronic inflammation and immune alterations in the lung may facilitate tumor growth.

• Studies report high rates of persistent symptoms (fatigue, breathlessness) and radiographic abnormalities (ground-glass opacities, fibrosis) up to 6–12 months post-infection 11 13 15.
• Decreased functional capacity and quality of life are common after severe respiratory viral infections, with many patients not fully recovering by one year 13 15.
• Long-term organ dysfunction—including pulmonary, cardiovascular, and other systems—has been observed, emphasizing the need for ongoing monitoring 12 14.
• The new study connects these chronic inflammatory sequelae to potential cancer risk, suggesting that pro-tumor immune environments may persist after infection 13 14.

How do viral infections impact cancer patients' outcomes?

Multiple studies show that cancer patients, particularly those with lung cancer, hematologic malignancies, or advanced disease, are more vulnerable to severe complications and death from influenza and COVID-19. The new study focuses on infection as a risk factor for later cancer development, while most prior research emphasizes acute outcomes.

• Cancer patients have higher hospitalization rates, complications, and mortality after respiratory viral infections than non-cancer populations 1 2 9 10.
• Lung cancer and hematologic malignancy patients are at particularly high risk for pneumonia, lower respiratory tract infection, and death following influenza or COVID-19 2 7 8 9 10.
• Immunosuppression, recent cancer therapy, and comorbidities increase infection severity in cancer patients 1 7 8.
• While acute infection outcomes have been well-studied, the new work highlights a need to monitor for late-onset lung cancer in those with prior severe infection 6.

Can vaccination reduce risks associated with severe respiratory infection?

Annual influenza vaccination is widely recommended for cancer patients to reduce the risk of infection and associated complications. The new study adds that vaccination may also prevent immune alterations linked to increased lung cancer risk after severe infection.

• Evidence supports annual influenza vaccination and prompt antiviral therapy for cancer patients to reduce morbidity and mortality 10.
• The new research suggests that vaccination can prevent many of the persistent immune changes in the lung that are associated with subsequent cancer risk 10.
• By reducing the likelihood of severe infection, vaccination may indirectly lower the risk of long-term complications, including cancer 10.
• These findings reinforce public health strategies promoting vaccination, especially for high-risk groups 10.

Future Research Questions

Although this study provides important new insights, substantial questions remain regarding the mechanisms, magnitude, and broader implications of infection-associated cancer risk. Further research is needed to clarify causality, identify high-risk subgroups, and develop effective prevention and surveillance strategies.

Research Question	Relevance
Does vaccination against COVID-19 or influenza reduce long-term lung cancer risk?	Understanding the protective effect of vaccination could inform cancer prevention strategies and public health recommendations 10.
What are the precise immune mechanisms linking severe respiratory infection to lung cancer development?	Identifying the cellular and molecular pathways could enable targeted interventions to mitigate cancer risk after infection 6.
Which patient subgroups are at highest risk for post-infection lung cancer?	Determining risk factors such as age, smoking, comorbidities, or genetic predispositions can focus surveillance and preventive measures 2 4 6.
How long does the pro-tumor lung environment persist after severe infection?	Clarifying the duration of elevated cancer risk will help guide optimal timing and duration of clinical monitoring 6 13 15.
Can therapeutic modulation of post-infection lung inflammation reduce cancer risk?	Exploring anti-inflammatory or immunomodulatory interventions may offer new strategies to prevent infection-associated lung cancer 6.